Clinical trials: Stage III Skin Cancer
Melanoma
Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
The purpose of this research study is to see if the combination of HSPPC-96 and ipilimumab is safe and effective in the treatment of advanced melanoma.
- Trial name
- NCT02452281
- Testing
- ipilimumab, HSPPC-96
- Where
- United States
- Sponsor
- Rabih Said
Breast Cancer
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in different ways may kill any tumor cells that remain after surgery.
- Trial name
- NCT00103181
- Testing
- 3-dimensional conformal accelerated partial breast irradiation, brachytherapy, whole breast irradiation
- Where
- 387 sites in United States, Canada and 2 more
- Volunteers
- 4,216 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105
RATIONALE: Studying samples of urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00959244
- Testing
- high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Nebraska
Bone Pain in Stage I - III Breast Cancer
NOLAN: Naproxen or Loratadine and Neulasta
The primary objective of the study is to estimate the difference in bone pain between breast cancer patients receiving chemotherapy and pegfilgrastim and either no prophylactic intervention, prophylactic naproxen, or prophylactic…
- Trial name
- NOLAN (NCT01712009)
- Testing
- Naproxen, Loratadine, Pegfilgrastim
- Where
- 83 sites in United States
- Volunteers
- 600 people
- Sponsor
- Amgen
Breast Cancer
Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831
This research study is looking at tissue samples from women with breast cancer who were treated on clinical trial NCCTG-N9831. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more…
- Trial name
- NCT00898898
- Testing
- diagnostic laboratory biomarker analysis
- Volunteers
- 2,837 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
This study was a companion study to CLEE011A2404 which provided the opportunity for the collection of tumor tissue samples to better understand relevant mutations and the mechanisms responsible for resistance to treatment.
- Trial name
- NCT03050398
- Testing
- Ribociclib, letrozole
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
This study will evaluate the efficacy, safety, and pharmacokinetics of inavolisib in combination with palbociclib and fulvestrant compared with placebo plus palbociclib and fulvestrant in participants with PIK3CA-mutant, hormone…
- Trial name
- INAVO120 (NCT04191499)
- Testing
- Inavolisib, Palbociclib, Fulvestrant
- Where
- 135 sites in United States, Argentina and 26 more
- Volunteers
- 325 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
The main purpose is to learn if adding bevacizumab to standard chemotherapy and trastuzumab to treat HER2-positive breast cancer will affect heart function.
- Trial name
- NCT00464646
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Where
- 36 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer, Stage II Breast Cancer
MARGetuximab Or Trastuzumab (MARGOT)
The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs.
- Conditions
- Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
- Trial name
- MARGOT (NCT04425018)
- Testing
- Paclitaxel, Pertuzumab, Margetuximab
- Where
- 14 sites in United States
- Volunteers
- 174 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Chemotherapy
Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm
This is a multi-center randomized phase III trial. The purpose is to evaluate and compare the pathological complete response (pCR) rates after neoadjuvant chemotherapy with tailored chemotherapeutic regimens or standard…
- Trial name
- TaiNAC (NCT00776724)
- Testing
- Taxotere , Epirubicin, E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP
- Where
- Taiwan
- Volunteers
- 166 people
- Sponsor
- National Taiwan University Hospital
Melanoma Stage III
The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma
This study is being conducted to explore the efficacy and safety of neoadjuvant toripalimab combined with temozolomide in resectable stage III melanoma.
- Trial name
- NCT05827770
- Testing
- Toripalimab combined with Temozolomide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Yong Chen
Advanced Breast Cancer
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)
Randomized phase III trial of trastuzumab + Alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced Breast cancer.
- Trial name
- ALPHABET (NCT05063786)
- Testing
- Trastuzumab, Alpelisib, Fulvestrant
- Where
- 106 sites in Austria, France and 4 more
- Volunteers
- 27 people
- Sponsor
- Spanish Breast Cancer Research Group
Adult Solid Neoplasm, Estrogen Receptor Negative
Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
This phase I trial studies the side effects and the best dose of cilengitide when given together with paclitaxel weekly in treating patients with solid tumors that have spread nearby or to other areas of the body and cannot be…
- Conditions
- Adult Solid Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma
- Trial name
- NCT01276496
- Testing
- Cilengitide, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
RBX7455 Before Surgery for the Treatment of Operable Breast Cancer
This clinical trial studies the side effects and possible benefits of RBX7455 given before surgery in treating patients with breast cancer that can be removed by surgery (operable).
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04139993
- Testing
- Microbiota-based Formulation RBX7455
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Breast Cancer
Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer
Phase III Clinical Trial to Compare the Efficacy and the Safety of AC(Doxorubicin, Cyclophosphamide) Followed by 4 Cycles Taxotere Versus AC(Doxorubicin, Cyclophosphamide) Followed by 4 Cycles Nanoxel M as Neoadjuvant…
- Trial name
- NCT05207514
- Testing
- Nanoxel M, Taxotere, Doxorubicin
- Where
- South Korea
- Volunteers
- 26 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Gastrointestinal Stromal Tumor of Rectum
Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST
Prior to the implementation of preoperative imatinib mesylate therapy, a considerable percentage (ranging from 34.5% to 67.5%) of individuals diagnosed with rectal gastrointestinal stromal tumors (GIST) underwent abdominoperineal…
- Trial name
- PIRKER (NCT05970900)
- Testing
- Imatinib Mesylate, Local resection
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Fujian Medical University Union Hospital
Breast Cancer
Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer
The purpose of this research study is to study the effects (good and bad) of bevacizumab alone, bevacizumab with low-dose continuous chemotherapy (called metronomic chemotherapy), or bevacizumab with capecitabine, on you and your…
- Trial name
- NCT00121134
- Testing
- Bevacizumab, Cyclophosphamide, Methotrexate
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Harold J. Burstein, MD, PhD
Breast Cancer
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
- Trial name
- BETH (NCT00625898)
- Testing
- Docetaxel, Trastuzumab, Carboplatin
- Where
- 649 sites in United States, Argentina and 38 more
- Volunteers
- 3,509 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer
Recent clinical studies showed that triple-negative breast cancer patients (ER-/PR-/HER2-) may benefit more from Capecitabine chemotherapy.
- Trial name
- NCT01642771
- Testing
- 5-Fu/epirubicin/CTX following Docetaxel, Docetaxel/capecitabine followed by XEC
- Where
- 37 sites in China
- Volunteers
- 636 people
- Sponsor
- China Breast Cancer Clinical Study Group
Melanoma (Skin)
A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma
RATIONALE: Buthionine sulfoximine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00661336
- Testing
- buthionine sulfoximine, melphalan, microarray analysis
- Where
- 2 sites in United States
- Sponsor
- Duke University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.